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Abstract
Background: In immune-mediated diseases of the central nervous system, astrocytes exposed to interferon-γ
(IFN-γ) can express major histocompatibility complex (MHC) class II molecules and antigens on their surface.
MHC class II molecules are thought to be delivered to the cell surface by membrane-bound vesicles. However,
the characteristics and dynamics of this vesicular traffic are unclear, particularly in reactive astrocytes, which
overexpress intermediate filament (IF) proteins that may affect trafficking. The aim of this study was to determine
the mobility of MHC class II vesicles in wild-type (WT) astrocytes and in astrocytes devoid of IFs.
Methods: The identity of MHC class II compartments in WT and IF-deficient astrocytes 48 h after IFN-γ activation
was determined immunocytochemically by using confocal microscopy. Time-lapse confocal imaging and
Alexa Fluor546-dextran labeling of late endosomes/lysosomes in IFN-γ treated cells was used to characterize the
motion of MHC class II vesicles. The mobility of vesicles was analyzed using ParticleTR software.
Results: Confocal imaging of primary cultures of WT and IF-deficient astrocytes revealed IFN-γ induced MHC class II
expression in late endosomes/lysosomes, which were specifically labeled with Alexa Fluor546-conjugated dextran.
Live imaging revealed faster movement of dextran-positive vesicles in IFN-γ-treated than in untreated astrocytes.
Vesicle mobility was lower in IFN-γ-treated IF-deficient astrocytes than in WT astrocytes. Thus, the IFN-γ-induced
increase in the mobility of MHC class II compartments is IF-dependent.
Conclusions: Since reactivity of astrocytes is a hallmark of many CNS pathologies, it is likely that the up-regulation
of IFs under such conditions allows a faster and therefore a more efficient delivery of MHC class II molecules to the
cell surface. In vivo, such regulatory mechanisms may enable antigen-presenting reactive astrocytes to respond
rapidly and in a controlled manner to CNS inflammation.
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Background
Antigen-presenting cells (APCs) are key players in the im-
mune response. They take up and process exogenous anti-
gens and present them to CD4 helper T-cells, resulting in
antigen-specific T-cell activation. After endocytosis of anti-
gens by APCs, early endosomes gradually transform into
late endosomes/lysosomes, where antigens are processed
to peptides and loaded onto MHC class II molecules. Late
endosomes/lysosomes expressing peptide-MHC class II
complexes are delivered to the cell surface for recognition
by T-cell receptors on CD4 helper T-cells [1,2].
Astrocytes, the most abundant glial cells in the central
nervous system (CNS), can act as ‘non-professional’
APCs. Unlike professional APCs (for example, dendritic
cells, macrophages, B-cells), astrocytes express cell-
surface MHC class II molecules only upon exposure to
the cytokine IFN-γ [3,4]. IFN-γ-activated astrocytes
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participate in antigen presentation and activation of CD4
helper T-cells in immune-mediated CNS disorders such
as multiple sclerosis [5,6] and in experimental auto-
immune encephalomyelitis [3]. Expression of MHC II
molecules in astrocytes is thought to be controlled by
neurons, since IFN-γ induces MHC class II expression
only in slice culture zones containing degenerated neu-
rons, in which spontaneous neuronal activity (for example,
release of glutamate or noradrenaline) is suppressed
[7,8]. In primary astrocyte cultures without neurons,
IFN-γ induces expression of surface MHC class II and
some APC-specific co-stimulatory molecules [9,10]. Such
cultures may be useful for studying antigen presentation
at the subcellular level.
The trafficking of MHC class II compartments in
APCs is dependent on the cytoskeletal network. This
trafficking is influenced by actin microfilaments [11] and
actin-based motor proteins in B-cells [12] and by micro-
tubules and microtubule-based motor proteins in den-
dritic cells and a human melanoma cell line [13,14]. The
MHC class II compartments in astrocytes and their mo-
bility have not been characterized.
In reactive astrocytes, which are found in almost all
CNS pathologies, the expression of IF proteins (cell-type-
specific components of the cytoskeleton) [15] is up-
regulated [16,17]. Studies of primary astrocytes from
mice deficient in the IF proteins glial fibrillary acidic pro-
tein and vimentin (GFAP-/-Vim-/-) and completely devoid
of astrocyte cytosolic IFs [18,19] have suggested that the
up-regulation of IFs in pathological situations may de-
regulate vesicle trafficking [19,20].
In this study, we sought to determine whether the traf-
ficking of MHC class II compartments, which is closely
associated with neuroinflammation, involves IFs. Live im-
aging revealed faster movement of dextran-positive vesi-
cles in IFN-γ-treated than in untreated astrocytes. These
compartments enriched with MHC class II molecules
upon IFN-γ treatment, were less mobile in cytosolic IF-
deficient (GFAP-/-Vim-/-) than in WT astrocytes, indicat-
ing that the IFN-γ-induced increase in the mobility of




Astrocyte cultures were prepared from the cerebrum of
1-day-old GFAP-/-Vim-/- and WT mice on a mixed
C57Bl6/129Sv/129Ola genetic background and main-
tained as described [18,21-23]. GFAP-/-Vim-/- mice
[18,24] were obtained by cross-breeding mice lacking
GFAP [22] and mice lacking Vim [25]. Before experi-
ments, the cells were removed from the culture flasks
with trypsin/EDTA and plated on 22-mm glass coverslips
coated with poly-L-lysine. Cells were maintained in high-
glucose Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum, 1 mM sodium pyruvate,
2 mM L-glutamine, and 25 μg/mL penicillin-streptomycin
in an atmosphere of humidified air (95%) and CO2 (5%). In
some experiments, astrocytes were treated with 600 U/ml
IFN-γ (0.06 μg/mL; Abcam, Cambridge, UK) for 48 h at
37°C. The purity of astrocyte cultures was confirmed
with antibodies against astrocytic markers GFAP (Sigma
Aldrich, St Louis, MO, USA) or glutamine synthetase
(Abcam, Cambridge, MA, USA). All chemicals were
from Sigma Aldrich (St Louis, MO, USA) unless noted
otherwise.
The care for experimental animals was in accordance
with International Guiding Principles for Biomedical Re-
search Involving Animals developed by the Council for
International Organizations of Medical Sciences and
Directive on Conditions for issue of License for Animal
Experiments for Scientific Research Purposes (Official
Gazette of the RS, No. 43/07).
Flow cytometry
Cell-surface expression of MHC class II molecules was
determined by flow cytometry (FACSCalibur, BD Bios-
ciences, Franklin Lakes, NJ, USA) and fluorescence-
labeled rat Alexa Fluor488 anti-mouse I-A/I-E (MHC class
II) antibodies (BioLegend, San Diego, CA, USA). Control
and IFN-γ-activated mouse WT and GFAP-/-Vim-/- astro-
cytes were removed from flasks with trypsin/EDTA and
collected by centrifugation. Antibody was added, and the
cells were incubated at room temperature for 15 min in
the dark, washed twice with Dulbecco’s phosphate-
buffered saline, and resuspended in 2% paraformaldehyde.
Alexa Fluor488-IgG2b cocktail (BioLegend) was used as an
isotype control. From a forward scatter and side scatter
dot plot, the population of cells was gated for further ana-
lysis. Cell-surface expression of MHC class II molecules
was determined by fluorescence-activated cell sorting.
Immunostaining
Control and IFN-γ-activated astrocytes growing on cov-
erslips were fixed in 2% paraformaldehyde for 5 min at
room temperature and treated with 10% goat serum for
1 h at 37°C. In some experiments, astrocytes were incu-
bated with fixable 10-kDa Alexa Fluor546 dextran conju-
gate (0.1 mg/mL; Molecular Probes, Invitrogen, Eugene,
OR, USA) for 16 h at 37°C and washed for 3 h at 37°C.
Cultures were then stained with one or both of the fol-
lowing primary antibodies for 2 h at 37°C: Alexa Fluor488
rat anti-mouse MHC class II (1:200) and rabbit anti-
lysosomal-associated membrane protein 1 (LAMP1;
1:250; Abcam). Excess primary antibody was washed off,
and the cultures were incubated for 1 h at 37°C with
Alexa Fluor546- or Alexa Fluor488-conjugated secondary
goat anti-rabbit IgG antibody (1:600; Abcam). Excess
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antibody was removed, and cells were treated with Slow-
Fade Gold antifade reagent (Molecular Probes). Immu-
nolabeled cells were imaged with an inverted Zeiss LSM
510 or Zeiss LSM 510 Meta confocal microscopes with
an oil-immersion plan apochromatic objective (63x, 1.4
NA; Carl Zeiss, Jena, Germany), using 488-nm Ar-Ion
and 543-nm He-Ne laser excitation. Emission light was
acquired sequentially with a 505-530-nm bandpass emis-
sion filter (Alexa Fluor488) and a 560-nm long-pass emis-
sion filter (Alexa Fluor546).
Time-lapse confocal imaging
Astrocytes were loaded with 0.1 mg/mL Alexa Fluor546-
dextran (Molecular Probes) for 16 h at 37°C, washed for
3 h at 37°C, and transferred to the chamber for imaging.
Time-lapse fluorescence images (512 x 512 pixels) were
obtained every 2 s for 3 min (90 frames) with the Zeiss
LSM 510 Meta confocal microscope described above
and 543-nm He-Ne laser excitation. Emission light was
acquired with a 560-nm long-pass emission filter. Sixty
seconds after the start of recording cells were superfused
with 1 mM ATP in a standard saline solution (10 mM
Hepes/NaOH, pH 7.2, 10 mM D-glucose, 131.8 mM
NaCl, 1.8 mM CaCl2, 2 mM MgCl2, and 5 mM KCl).
Vesicle mobility
The motion of Alexa Fluor546-dextran–labeled vesicles
before and 30 s after the start of ATP stimulation was
tracked in exported TIFF files by ParticleTR software
(Celica, Ljubljana, Slovenia) as described [23]. A single
dextran-labeled vesicle was selected in the image se-
quence. Using a simplex algorithm with a least-squares
estimator, the software fits a 2D Gaussian curve to the
vesicle intensity profile. The peak of curve was recorded
as the x,y coordinates of the vesicle position. The time
(from the beginning of tracking for a single vesicle), step
length (displacement of a vesicle over 2 s), TL (total
length of the analyzed vesicle pathway), and MD (meas-
ure of a net translocation of vesicle) were determined
[19,23]. Vesicle mobility in control and IFN-γ-activated
astrocytes before and after ATP stimulation was ana-
lyzed in 40 cells from five independent mouse WT astro-
cyte cultures and in 33 cells from four independent
mouse GFAP-/-Vim-/- astrocyte cultures. Vesicle mobility
was analyzed for 30 s (15 frames).
Statistical analysis
Data are presented as mean± s.e.m. Differences in TL
and MD were analyzed by t test. Differences in the frac-
tion of vesicles exhibiting directional mobility were ana-
lyzed with Fisher’s exact test. Differences between the
slopes were analyzed by Analysis of covariance. P<0.05
was considered significant.
Results
IFN-γ induces expression of MHC class II molecules on
GFAP-/-Vim-/- astrocytes
To determine whether MHC class II molecules are
expressed on the surface of IF-deficient astrocytes, we
exposed primary cultures of WT and GFAP-/-Vim-/-
astrocytes to IFN-γ for 48 h. Cell-surface expression of
MHC class II molecules was much more abundant in
control WT and GFAP-/-Vim-/- cells treated with IFN-γ
than in non-treated cells (Figure 1). Although the frac-
tion of low fluorescence intensity MHC class II positive
cells upon IFN-γ treatment was slightly higher than in
IFN-γ treated GFAP-/-Vim-/- astrocytes (Figure 1, lower
panels), IFs are not required for expression of MHC
class II molecules on the surface of astrocytes.
Fluorescent dextran labels MHC class II–positive late
endosomes/lysosomes in WT and GFAP-/-Vim-/- astrocytes
Before reaching the cell surface of APCs, MHC class II
molecules are generally located in late endosomal/lyso-
somal compartments of APCs [1] with diameters above
200 nm [26,27], which can be specifically labeled by
long-term loading of cells with fluorescent dextrans [28].
We used this approach to label and study the mobility of
late endosomes/lysosomes expressing MHC class II
molecules in IFN-γ-activated WT and IF-deficient astro-
cytes. First, we determined whether dextran labels late
endosomes/lysosomes in WT and GFAP-/-Vim-/- astro-
cytes and whether these compartments express MHC
class II molecules upon IFN-γ stimulation. The cells
were preloaded with Alexa Fluor546-dextran for 16 h and
washed with dextran-free medium for 3 h to clear dex-
tran from the early endosomal compartments [28,29].
WT and GFAP-/-Vim-/- astrocytes internalized dextran
without any stimulation (Figure 2), consistent with pre-
vious studies of the endocytosis of dextrans [28,30] and
FM-dyes [31,32] in astrocytes. Fluorescent dextran was
found in punctate structures in the perinuclear region
and throughout the cytoplasm.
To verify that the dextran-labeled structures were late
endosomes/lysosomes, we fixed and stained the cells
with antibodies against LAMP1, a marker of late endo-
somes/lysosomes. In both WT and GFAP-/-Vim-/- astro-
cytes, internalized Alexa Fluor546-dextran was highly
colocalized with LAMP1 (Figure 2). Thus, the lack of IFs
in GFAP-/-Vim-/- astrocytes does not affect long-term
dextran loading into late endosomes/lysosomes.
Next we examined whether dextran-labeled late endo-
somes/lysosomes express MHC class II molecules when
treated with IFN-γ. After a 48-h exposure to IFN-γ, cells
were labeled with Alexa Fluor546-dextran and antibodies
against MHC class II molecules. MHC class II molecules
were present in vesicles in treated GFAP-/-Vim-/- and WT
cells but not in untreated cells (Figure 3). Internalized
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Alexa Fluor546-dextran was highly colocalized with MHC
class II molecules (Figure 3a, b, lower panels), indicating
that dextran was transported into the MHC class II-
enriched compartments. To further characterize these
compartments, we double labeled IFN-γ-activated cells
with antibodies against MHC class II molecules and
LAMP1. MHC class II molecules colocalized with
LAMP1 in WT and GFAP-/-Vim-/- astrocytes stimulated
with IFN-γ (Figure 4).
Increased mobility of dextran-labeled vesicles in
IFN-γ-activated astrocytes requires IFs
Next we used dextran labeling and time-lapse confocal
imaging to study the mobility of late endosomes/lyso-
somes in living astrocytes. To determine whether
vesicle mobility in IFN-γ-treated cells is dependent on
cytosolic Ca2+ levels, we exposed the cells to 1 mM
ATP to increase cytosolic [Ca2+] [33,34]. Cells were
imaged every 2 s for 30 s (15 frames) to determine the
maximal displacement (MD) and the track length (TL)
of vesicles.
Dextran-labeled vesicles moved in the cytoplasm of
WT astrocytes (Figure 5a; see also the movies Additional
files 1, 2) [32]. In IFN-γ-stimulated cells, where the ma-
jority of dextran-labeled vesicles were enriched with
MHC class II molecules (Figure 3), the vesicle tracks were
longer than in control cells. TL increased by 36.4%
(P<0.05) and MD by 69.4% (P<0.05) (Figure 5c, d,
Table 1). Thus, IFN-γ increases the mobility of dextran-
labeled vesicles. In GFAP-/-Vim-/- astrocytes, dextran-
labeled vesicles continued to move (Figure 5b, see also
the movies Additional files 3, 4) but did so more slowly
than in WTastrocytes, and the IFN-γ-induced increase in
mobility was smaller than in WT astrocytes. TL increased
by 5.3% and MD by 10.3% (P<0.05) (Figure 5c, d,
Table 1).
After ATP stimulation (Figure 5, Table 1, see also the
movies Additional files 5, 6), the mobility of dextran-
labeled vesicles was reduced in control and IFN-γ-
treated WT astrocytes. In control WT cells, TL
decreased by 10.4% and MD by 16.3% (P<0.05). In IFN-
γ-treated WT astrocytes, the decreases were larger. TL
decreased by 28.0% and MD by 43.4% (P<0.05). Thus,
the mobility of dextran-labeled vesicles in control and in
IFN-γ-activated WT astrocytes depends on cytosolic
[Ca2+].
Stimulation with ATP did not reduce the mobility of
dextran-labeled vesicles in control GFAP-/-Vim-/- astro-
cytes but did in IFN-γ-activated GFAP-/-Vim-/- astrocytes
(Figure 5, Table 1; see also the movies Additional files 7, 8).
TL was reduced by 10.7% andMD by 16.3% (P<0.05).
IFN-γ increases the proportion of directional vesicles in
WT astrocytes
Next we analyzed the effect of IFN-γ on the directional
mobility of vesicles. Dextran-labeled vesicles in WT and
Figure 1 IFN-γ induces MHC class II expression on WT and GFAP-/-Vim-/- deficient mouse astrocytes. Cell-surface expression of MHC class II
molecules on WT (left) and GFAP-/-Vim-/- (right) astrocytes was analyzed by flow cytometry in the absence (Ctrl.) and 48 h after the addition of
600 U/ml IFN-γ (+IFN-γ). Note that in WT cells, the fraction of low fluorescence intensity MHC class II positive cells upon IFN-γ treatment appears
to be higher than in IFN-γ treated GFAP-/-Vim-/- astrocytes. Dotted lines indicate isotype controls; solid lines indicate anti-Alexa Fluor488-MHC class
II antibodies. The results are representatives of four independent experiments.
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GFAP-/-Vim-/- astrocytes exhibited two types of mobility
(Figure 6): directional (MD >1 μm) and non-
directional (MD <1 μm) [19,23]. In WT and GFAP-/-
Vim-/- astrocytes, the slopes of regression lines for
mobility data of directional and non-directional vesicles
differed before and after ATP treatment (P<0.001,
Figure 6, Table 2). Treatment with IFN-γ increased the
proportion of vesicles with directional mobility in WT
Figure 2 Alexa Fluor546-dextran labels late endosomes/lysosomes in WT and GFAP-/-Vim-/- mouse astrocytes. Fluorescence images of WT
(a) and GFAP-/-Vim-/- (b) astrocytes labeled with dextran and immunostained with antibodies against LAMP1, a marker of late endosomes/
lysosomes. Merged images (overlay) show that the majority of dextran puncta are colocalized with LAMP1 puncta. Lower panels (insets) show
boxed regions at higher magnification. Scale bars: 10 μm, 2 μm (insets). Arrowheads point to typical structures expressing both signals. Note that
the green signal corresponding to the membrane bound LAMP-1 signal encircles the luminal signal of red dextran.
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astrocytes (from 8.0% to 20.3%, P<0.001) but not in
GFAP-/-Vim-/- astrocytes (4.4% vs. 5.7%, P= 0.081)
(Figure 6), suggesting that the effect of IFN-γ on
directional mobility of vesicles involves IFs.
The fraction of vesicles with directional mobility was
smaller in control and IFN-γ-treated GFAP-/-Vim-/-
astrocytes than in control and IFN-γ-treated WT astro-
cytes (4.4% vs. 8.0% and 5.7% vs. 20.3%, respectively;
Figure 3 Alexa Fluor546-dextran labels MHC class II–positive compartments in IFN-γ-treated WT and GFAP-/-Vim-/- mouse astrocytes.
Fluorescence images of control (Ctrl.) and IFN-γ-treated (+IFN-γ) WT (a) and GFAP-/-Vim-/- (b) astrocytes labeled with dextran, fixed, and
immunostained with antibodies against MHC class II molecules. IFN-γ induces punctuate expression of MHC class II molecules. White pixels (mask)
represent the colocalization mask of green (MHC II) and red fluorescence pixels (dextran). Note that the threshold value of 51 arbitrary units of
255 intensity levels, which corresponds to 20% of the maximum intensity level, was selected to separate the background intensity levels from the
signal of single red and green pixels. Scale bars: 10 μm.
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P<0.001) (Figure 6, upper panels), indicating that IFs
affect the directional mobility of vesicles in control
[19,23] and IFN-γ-treated astrocytes.
Stimulation with ATP decreased the percentage of dir-
ectionally mobile dextran-labeled vesicles in control
(8.0% vs. 5.2%, P<0.01) and IFN-γ-treated WT astro-
cytes (20.3% vs. 5.9%, P<0.001) (Figure 6a), as well as in
control (4.4% vs. 3.9%, P = 0.602) and IFN-γ-treated
GFAP-/-Vim-/- astrocytes (5.7% vs. 2.5%, P<0.001)
(Figure 6b).
Figure 4 MHC class II molecules are expressed in late endosomes/lysosomes in IFN-γ-activated WT and GFAP-/-Vim-/- mouse astrocytes.
Fluorescence images of IFN-γ-activated WT (a) and GFAP-/-Vim-/- (b) astrocytes after immunostaining with antibodies against LAMP1 and
MHC class II molecules. The two signals overlap to a great extent (overlay), indicating that IFN-γ induces expression and localization of MHC class
II molecules in late endosomes/lysosomes in WT and GFAP-/-Vim-/- astrocytes. Lower panels (insets) show boxed regions at higher magnification.
Scale bars: 10 μm; 2 μm (insets). Arrowheads point to typical structures expressing both signals.
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Discussion
This study shows that IFN-γ induces an IF-dependent
increase in the mobility of MHC class II compartments
in astrocytes. Our findings suggest that up-regulation of
IFs in reactive astrocytes allows faster and therefore
more efficient delivery of MHC class II molecules to the
cell surface.
The expression and targeting of MHC class II molecules in
IFN-γ-activated astrocytes
In WT and GFAP-/-Vim-/- primary mouse astrocytes,
IFN-γ induced expression of MHC class II molecules on
the cell surface and in vesicular structures. As in profes-
sional APCs [1], MHC class II expression colocalized
with dextran and LAMP1, which are markers of late
endosomes/lysosomes. Thus, although IFs are the key
structural and functional element in reactive astrocytes
[16,24,35] - and may participate in protein targeting
defects in polarized epithelial cells [15], lymphocytes and
endothelial cells [36], dorsal root ganglion neurons [37],
and fibroblasts [38] - the lack of IFs in astrocytes does
not affect the distribution of late endosomal/lysosomal
markers or MHC class II expression in these organelles
48 h after IFN-γ activation. Interestingly, the distribution
of the late endosomal/lysosomal markers LAMP1 and
CD63 is altered in Vim-/- fibroblasts [38].
IFN-γ induces an IF-dependent increase in the mobility of
MHC class II compartments in astrocytes
IFs can deregulate trafficking of vesicular glutamate
transporter 1, atrial natriuretic peptide, and acidic vesi-
cles in astrocytes [19,20] and participate in the transport
and distribution of mitochondria in neurons [39], Golgi
complexes in COS-7 cells [40], late endosomes/lyso-
somes in fibroblasts [38], and melanosomes in melano-
phores [41]. To study the effect of IFs on the trafficking
of MHC class II molecules in IFN-γ-activated astrocytes,
we used confocal live imaging and dextran loading of
late endosomes/lysosomes [28,29], which are in IFN-γ-
activated astrocytes enriched with MHC class II
molecules.
Dextran-labeled vesicles moved slower in GFAP-/-
Vim-/- astrocytes than in WT astrocytes, indicating that
the lack of IFs does not affect the distribution of late
endosomes/lysosomes but reduces their mobility. In WT
astrocytes, IFN-γ greatly enhanced the mobility of
dextran-labeled vesicles, increasing TL by 36.4% and
MD by 69.4%. But in GFAP-/-Vim-/- astrocytes, the IFN-
γ-induced increase was remarkably attenuated. TL
increased by only 5.3% and MD by 10.2%. In WT astro-
cytes, IFN-γ increased the percentage of directionally
mobile vesicles, and some vesicles in both treated and
control cells exhibited bidirectional mobility [42]. In
IFN-γ-activated GFAP-/-Vim-/- astrocytes, however, the
percentage of directionally mobile vesicles increased
only slightly. Clearly, IFs help regulate the mobility of
MHC class II-positive compartments in IFN-γ-activated
astrocytes.
In activated dendritic cells, microtubules drive the direc-
tional transport of MHC class II-positive tubules from late
endosomes/lysosomes to the plasma membrane [43,44]
and their bidirectional movement [14]. Microtubules and
actin filaments also help regulate the mobility of MHC
class II compartments in antigen-presenting B-cells
(See figure on previous page.)
Figure 5 IFN-γ induces a larger increase in the mobility of dextran labeled vesicles in WT than in GFAP-/-Vim-/- mouse astrocytes. (a, b)
Top, representative fluorescence images of a control (Ctrl.) and an IFN-γ-treated (+IFN-γ) WT astrocyte (a) and a GFAP-/-Vim-/- astrocyte (b) labeled
with dextran. Bottom, trajectories of dextran-loaded vesicles in an exemplary cell before (Spon.) and after treatment with 1 mM ATP (ATP). The
tracks of individual vesicles were monitored for 30 s (see also the movies, Additional files 1, 2, 3, 4, 5, 6, 7, 8). Vesicle tracks were longer in WT and
GFAP-/-Vim-/- cells treated with IFN-γ than in untreated cells. ATP decreased vesicle mobility. Scale bars: 10 μm. (c) Histogram of average vesicle TLs
in control (Ctrl.) and IFN-γ-treated (+IFN-γ) WT and GFAP-/-Vim-/- cells. (d) Histogram of mean MDs of vesicles in control (Ctrl.) and IFN-γ-treated
(+IFN-γ) WT and GFAP-/-Vim-/- cells. Numbers on graphs are numbers of analyzed vesicles. Values are mean± s.e.m. *P<0.05.
Table 1 Mobility of vesicles in control and IFN-γ-treated WT and GFAP-/-Vim-/- astrocytes under spontaneous conditions
and after ATP stimulation
Genotype Stimulation Control IFN-γ
TL (μm) MD (μm) n TL (μm) MD (μm) n
WT Spontaneous 1.73 ± 0.02 0.49 ± 0.01 1900 2.36 ± 0.04a 0.83 ± 0.02a 2100
ATP 1.55 ± 0.02b 0.41 ± 0.01b 950 1.70 ± 0.02b 0.47 ± 0.01b 1050
GFAP-/-Vim-/- Spontaneous 1.51 ± 0.01 0.39 ± 0.01 1700 1.59 ± 0.02a 0.43 ± 0.01a 1600
ATP 1.49 ± 0.02 0.37 ± 0.01 850 1.42 ± 0.02b 0.36 ± 0.01b 800
Values are mean ± s.e.m.
n, number of vesicles.
aP< 0.05 vs. controls.
bP< 0.05 vs. spontaneous conditions.
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[11,12] and in a human melanoma cell line (Mel JuSo)
[13]. Since IFs in various cell types interact with microfila-
ments, microtubules, and the motor proteins myosin V,
kinesin, and dynein [45,46], the increase in the mobility of
MHC class II compartments in IFN-γ-treated astrocytes
may reflect up-regulation of IFs [16,47] and the resulting
qualitative or quantitative changes in the interaction be-
tween IFs and other components of the cytoskeleton.
These three cytoskeletal systems may jointly regulate the
trafficking and final positioning of MHC class II molecules
in IFN-γ-activated astrocytes.
Proposed (patho)physiological role of IFs in the sorting of
MHC class II molecules in IFN-γ-activated astrocytes
Our findings suggest that IFs are involved in the traffick-
ing of MHC class II compartments. Although the lack of
IFs attenuated the IFN-γ-induced increase in mobility,
MHC class II molecules reached the surface of WT and
GFAP-/-Vim-/- astrocytes. What is the role of IFs in the
sorting of MHC class II molecules in IFN-γ-activated
astrocytes? We propose that up-regulation of IF protein
expression [16,47] in antigen-presenting astrocytes facili-
tates the transport of antigen-loaded MHC class II mole-
cules from late endosomes/lysosomes in the perinuclear
region to the plasma membrane [13] and the recognition
of peptide-MHC class II complexes by T-cell receptors
on CD4 helper T-cells.
The pathway by which MHC class II molecules reach
the surface of APCs is poorly understood [1]. MHC class
II-containing compartments may directly fuse with the
plasma membrane [43,48]. In astrocytes treated with ATP
or glutamate, the fluorescence intensity of lysosomes la-
beled with FM dye decreases in Ca2+-dependent fashion,
indicating Ca2+-dependent lysosomal exocytosis in these
cells [49]. The authors propose that ATP or glutamate
stimulation causes the fusion pore to open briefly (kiss-
and-run fusion), releasing ATP molecules stored in lyso-
somes. In astrocytes, stronger and sustained elevation of
[Ca2+]i induced with Ca
2+ ionophores or by mechanical
stimulation triggers predominantly full fusion of lyso-
somes with the plasma membrane [31,49]. Both modes of
lysosomal exocytosis could deliver lysosomal membrane-
Figure 6 IFN-γ increases the proportion of directional dextran labeled vesicles in live WT mouse astrocytes. Graph shows MD as a
function of total TL over 30 s. Vesicles with MD >1 μm (dashed line) were characterized as directional vesicles (black circles; nd, number of
directional vesicles). Other vesicles were characterized as non-directional vesicles (white circles; nn, number of nondirectional vesicles). (a) The
percentage of directional vesicles in IFN-γ-treated WT cells was greater than in untreated control cells (20.3% vs. 8%; P<0.001). After ATP
treatment, the percentage of directional vesicles decreased from 8% to 5.2% (P<0.01) in control cells and from 20.3% to 5.9% in IFN-γ-treated WT
cells (P<0.001). (b) The percentage of directional vesicles in IFN-γ-treated GFAP-/-Vim-/- astrocytes did not change significantly compared to
untreated control cells (4.4% vs. 5.7%, P= 0.081). After ATP treatment, the percentage of directional vesicles was not affected in control cells
(4.4% vs. 3.9%; P= 0.602), but was reduced from 5.7% to 2.5% in IFN-γ-treated GFAP-/-Vim-/- cells (P<0.001). Note that the slopes of the lines fitted
for directional and non-directional vesicles are presented in Table 2.
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bound MHC class II molecules to the plasma membrane
[50,51].
Although ATP did not induce enhanced release of la-
beled dextran from late endosomes/lysosomes, which
would indicate lysosomal fusion [28,30,31], it is possible
that astrocytes use the lysosomal exocytotic machinery
[52] to deliver MHC class II molecules to the plasma
membrane. In lysosomes, the increase in [Ca2+]i in re-
sponse to ATP stimulation is delayed, usually by several
minutes [30,49]. Since we tracked the mobility of
dextran-labeled vesicles for 30 s after application of ATP,
we could not detect additional lysosomal fusion events.
However, when we treated astrocytes with 1 μM adren-
alin we did observe the release of labeled dextran from
late endosomes/lysosomes (unpublished data), implying
a role of cAMP in lysosomal exocytosis. ATP stimulation
reduced the mobility of late endosomes/lysosomes. In
non-secretory cells, the fraction of mobile lysosomes is
reduced after the addition of a Ca2+ ionophore, and in
astrocytes, the fraction of Lysotracker-labeled vesicles
containing atrial natriuretic peptide is reduced after
stimulation with ATP and Ca2+ ionophore [20,53].
The ATP-induced attenuation of vesicle mobility was
more apparent in the presence of IFs (Figure 5), imply-
ing a role for IFs in this process [20]. Reduced lysosomal
mobility may increase the probability that lysosomes will
dock and fuse with the plasma membrane. Thus, in
astrocytes functioning as APCs, an increase in [Ca2+]i
and cAMP (unpublished data) may trigger the delivery
of antigen-loaded MHC class II molecules from the lyso-
somal membrane to the plasma membrane.
Conclusions
The immune privilege of the CNS makes it crucial that
the activation of the immune system by resident im-
munocompetent astrocytes is strictly regulated. We show
here that IFN-γ induces the expression of MHC class II
molecules in otherwise immunologically silent astrocytes
and increases the mobility of vesicles enriched with
MHC class II molecules. The increase is highly
dependent on IFs, suggesting that the up-regulation of
IFs in reactive astrocytes allows faster and therefore more
efficient delivery of MHC class II-positive compartments
to the cell surface and the activation of CD4 helper T-
cells. Our data also suggest that besides IFN-γ activation,
astrocytes have a regulatory mechanism, involving
increases in [Ca2+]i, and cAMP that controls the fusion
of MHC class II compartments with the plasma mem-
brane and the final delivery of MHC class II molecules to
the cell surface. In vivo, such regulatory mechanisms
may enable antigen-presenting astrocytes to respond rap-
idly and in a controlled manner to CNS inflammation.
For better understanding of the role of astrocytes in CNS
pathologies, it will be essential to reveal in greater detail
the immunological function of astrocytes and the com-
plex regulatory mechanisms that enable these cells to
mediate immune responses in the CNS.
Table 2 Percentage of directional and non-directional vesicles before and after ATP treatment for control and
IFN-γ-treated WT and GFAP-/-Vim-/- astrocytes and slopes of the lines fitted to the vesicle mobility data
Genotype Stimulation Control IFN-γ
Mobility Slope (a ± s.e.m.)a Vesicle Slope (a ± s.e.m.)a Vesicle
(%) (%)
WT Spontaneous
Directional 0.633 ± 0.038c (152)b 8.0 0.575± 0.020c (426) 20.3
Non-directional 0.262 ± 0.006 (1748) 92.0 0.219± 0.005 (1674) 79.7
ATP
Directional 0.483 ± 0.056c (49) 5.2 0.597± 0.059c (62) 5.9
Non-directional 0.266 ± 0.009 (901) 94.8 0.231± 0.007 (988) 94.1
GFAP-/-Vim-/- Spontaneous
Directional 0.581 ± 0.068c (75) 4.4 0.553± 0.030c (92) 5.7
Non-directional 0.324 ± 0.008 (1625) 95.6 0.329± 0.009 (1508) 94.3
ATP
Directional 0.616 ± 0.069c (33) 3.9 0.781± 0.148c (20) 2.5
Non-directional 0.298 ± 0.010 (817) 96.1 0.279± 0.012 (780) 97.5
aThe slope values (a) ± s.e.m were obtained from the linear function fitted to the mobility data in Figure 6.
bValues inside brackets are numbers of vesicles. The slopes of regression lines for mobility data of directional and nondirectional vesicles differed in control and
IFN-γ treated WT and GFAP-/-Vim-/- cells under spontaneous conditions and after ATP treatment.
cP<0.001 vs. non-directional mobility.
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Additional files
Additional file 1: Mobility of dextran labeled vesicles in WT
astrocytes. The tracks of individual vesicles were monitored
for 30 s.
Additional file 2: Mobility of dextran labeled vesicles in IFN-γ
activated WT astrocytes. The tracks of individual vesicles were
monitored for 30 s.
Additional file 3: Mobility of dextran labeled vesicles in GFAP-/-
Vim-/- astrocytes. The tracks of individual vesicles were monitored
for 30 s.
Additional file 4: Mobility of dextran labeled vesicles in IFN-γ
activated GFAP-/-Vim-/- astrocytes. The tracks of individual vesicles were
monitored for 30 s.
Additional file 5: Mobility of dextran labeled vesicles in WT astrocytes
upon ATP stimulation. The tracks of individual vesicles were monitored
for 30 s.
Additional file 6: Mobility of dextran labeled vesicles in IFN-γ
activated WT astrocytes upon ATP stimulation. The tracks of
individual vesicles were monitored for 30 s.
Additional file 7: Mobility of dextran labeled vesicles in GFAP-/-
Vim-/- astrocytes upon ATP stimulation. The tracks of individual
vesicles were monitored for 30 s.
Additional file 8: Mobility of dextran labeled vesicles in IFN-γ
activated GFAP-/-Vim-/- astrocytes upon ATP stimulation. The tracks of
individual vesicles were monitored for 30 s.
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